Comparison of human papillomavirus type 18 (HPV-18) E6-mediated degradation of p53 in vitro and in vivo reveals significant differences based on p53 structure and cell type but little difference with respect to mutants of HPV-18 E6

Journal of General Virology

Volumn 79, Issue 8, 1998, Pages 1963-1970

  Gardiol, Daniela ^a   Banks, Lawrence ^a  

^a INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53; UBIQUITIN;

ANIMAL CELL; ARTICLE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN STRUCTURE; TEMPERATURE SENSITIVITY; VIRUS MUTANT; WART VIRUS;

ANIMALIA; DNA VIRUSES; HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPES; MURINAE; PAPILLOMAVIRUS;

EID: 0031847634     PISSN: 00221317     EISSN: None     Source Type: Journal    
DOI: 10.1099/0022-1317-79-8-1963     Document Type: Article

References (35)

1. Band, V., Dalal, S., Delmolino, L. & Androphy, E. J. (1993). Enhanced degradation of p53 protein in HPV-6 and BPV-1 E6-immortalized human mammary epithelial cells. EMBO Journal 12, 1847-1852.
2. Banks, L., Matlashewski, G. & Crawford, L. (1986). Isolation of human p53 specific monoclonal antibodies and their use in the studies of human p53 expression. European Journal of Biochemistry 159, 529-534.
3. Barbosa, M. S. S., Lowy, D. R. & Schiller, J. T. (1989). Papillomavirus polypeptides E6 and E7 are zinc-binding proteins. Journal of Virology 63, 1404-1407.
4. Chowdary, D. R., Dermody, J. J., Jha, K. K. & Ozer, H. L. (1994). Accumulation of p53 in a mutant cell line defective in the ubiquitin pathway. Molecular and Cellular Biology 14, 1997-2003.
5. Crook, T., Tidy, J. A. & Vousden, K. H. (1991). Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for p53 binding and trans-activation. Cell 67, 547-556.
6. Crook, T., Ludwig, R., Marston, N., Willkomm, D. & Vousden, K. (1996). Sensitivity of p53 lysine mutants to ubiquitin-directed degradation targeted by human papillomavirus E6. Virology 217, 285-292.
7. Dalal, S., Gao, Q., Androphy, E. J. & Band, V. (1996). Mutational analysis of human papillomavirus type 16 E6 demonstrates that p53 degradation is necessary for immortalization of mammary epithelial cells. Journal of Virology 70, 683-688.
8. Diller, L., Kassel, J., Nelson, C. E., Gryka, M. A., Litwak, G., Gebhardt, M., Bressac, B., Ozturk, M., Baker, S. J., Vogelstein, B. & Friend, S. H. (1990). p53 functions as a cell cycle control protein in osteosarcomas. Molecular and Cellular Biology 10, 5772-5781.
9. El-Deiry, W. S., Tokino, T., Velculescu, V. E., Lewy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Winzler, K. W. & Vogelstein, B. (1993). WAF1, a potential mediator of p53 tumor suppression. Cell 75, 817-825.
10. Foster, S. A., Demers, W., Etseheid, B. & Galloway, D. A. (1994). The ability of human papillomavirus E6 proteins to target p53 for degradation in vivo correlates with their ability to abrogate actinomycin D-induced growth arrest. Journal of Virology 68, 5698-5705.
11. Funk, W. D., Pak, D. T., Karas, R. H., Wright, W. E. & Shay, J. W. (1992). A transcriptionally active DNA-binding site for human p53 protein complexes. Molecular and Cellular Biology 12, 2866-2871.
12. Hollstein, M., Rice, K., Greenblatt, M. S., Soussi, T., Fuchs, R., Sorlie, T., Hovig, E., Smith-Sorensen, B., Montesano, R. & Harris, C. C. (1994). Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Research 22, 3551-3555.
13. Huibregtse, J. M., Scheffner, M. & Howley, P. M. (1991). A cellular protein mediates association of p53 with the E6 oncoprotein of human papillomavirus types 16 or 18. EMBO Journal 10, 4129-4135.
14. Huibregtse, J. M., Scheffner, M. & Howley, P. M. (1993). Localization of the E6-AP regions that direct human papillomavirus E6 binding, association with p53, and ubiquitination of associated proteins. Molecular and Cellular Biology 13, 4918-4927.
15. Isaacs, J., Chen, P., Garza, A., Hansen, M., Barrett, J. & Weissman, B. (1997). Failure of HPV E6 to rapidly degrade p53 in human HeLa x PNET cell hybrids. Oncogene 14, 1669-1678.
16. Kastan, M. B., Zhan, Q., El-Deiry, W. S., Carrier, P., Jacks, T., Walsh, W. V., Plunket, B. S., Vogelstein, B. & Fornace, A. J. (1992). A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 71, 587-597.
17. Kern, S. E., Kinzler, K. W., Bruskin, A., Jarosz, D., Friedman, P., Prives, C. & Vogelstein, B. (1991). Identification of p53 as a sequence-specific DNA-binding protein. Science 252, 1708-1711.
18. Kessis, T. D., Slebos, R. J., Nelson, W. G., Kastan, M. B., Plunkett, B. S., Han, S. M., Lorincz, A. T., Hedrick, L. & Cho, K. R. (1993). Human papillomavirus 16 E6 expression disrupts the p53-mediated cellular response to DNA damage. Proceedings of the National Academy of Sciences, USA 90, 3988-3992.
19. Lane, D. P. (1992). p53, guardian of the genome. Nature 358, 15-16.
20. Lechner, M. S., Mack, D. H., Finicle, A. B., Crook, T., Vousden, K. H. & Laimins, L. A. (1992). Human papillomavirus E6 proteins bind p53 in vivo and abrogate p53-mediated repression of transcription. EMBO Journal 11, 3045-3052.
21. Li, X. & Coffino, P. (1996). High-risk human papillomavirus E6 protein has two distinct binding sites within p53, of which only one determines degradation. Journal of Virology 70, 4509-4516.
22. Lin, D., Shields, M. Y., Ullrich, S. J., Apella, E. & Mercer, W. E. (1992). Growth arrest induced by wild -type p53 protein blocks cells prior to or near the restriction point in late G1 phase. Proceedings of the National Academy of Sciences, USA 89, 9210-9214.
23. Marston, N. J., Jenkins, J. R. & Vousden, K. H. (1995). Oligomerisation of full length p53 contributes to the interaction with mdm2 but not HPV E6. Oncogene 10, 1709-1715.
24. Matlashewski, G., Banks, L., Wu-Liao, J., Spence, P., Pim, D. & Crawford, L. (1986). The expression of human papillomavirus type 18 E6 protein in bacteria and the production of anti-E6 antibodies. Journal of General Virology 67, 1909-1916.
25. Matlashewski, G., Schneider, J., Banks, L., Jones, N., Murray, A. & Crawford, L. (1987). Human papillomavirus type 16 DNA cooperates with activated ras in transforming primary cells. EMBO Journal 6, 1741-1746.
26. Meek, D. W. (1994). Post-translational modification of p53. Seminars in Cancer Biology 5, 203-210.
27. Mietz, J. A., Unger, T., Huibregtse, J. M. & Howley, P. M. (1992). The transcriptional transactivation function of wild-type p53 is inhibited by SV40 large T-antigen and by HPV-16 E6 oncoprotein. EMBO Journal 11, 5013-5020.
28. Milne, D. M., McKendrick, L., Jardine, L. J., Deacon, E., Lord, J. M. & Meek, J. M. (1996). Murine p53 is phosphorylated within the pAb421 epitope by protein kinase C in vitro but not in vivo, even after stimulation with the phorbol ester O-tetradecanoylphorbol 13-acetate. Oncogene 13, 205-211.
29. Okamoto, K. & Beach, D. (1994). Cyclin G is a transcriptional target of the p53 tumor suppressor protein. EMBO Journal 13, 4816-4822.
30. Pim, D., Storey, A., Thomas, M., Massimi, P. & Banks, L. (1994). Mutational analysis of HPV-18 E6 identifies domains required for p53 degradation in vitro, abolition of p53 transactivation in vivo and immortalisation of primary BMK cells. Oncogene 9, 1869-1876.
31. Rolfe, M., Beer-Romero, P., Glass, S., Eckstein, J., Berdo, I., Theodoras, A., Pagano, M. & Draetta, G. (1995). Reconstitution of p53-ubiquitinylation reactions from purified components: the role of human ubiquitin-conjugating enzyme UBC4 and E6-associated protein (E6AP). Proceedings of the National Academy of Sciences, USA 92, 3264-3268.
32. Schaffner, M., Werness, B. A., Huibregtse, J. M., Levine, A. J. & Howley, P. M. (1990). The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promote the degradation of p53. Cell 63, 1129-1136.
33. Tarunina, M. & Jenkins, J. R. (1993). Human p53 binds DNA as a protein homodimer but monomeric variants retain full transcription transactivation activity. Oncogene 8, 3165-3173.
34. Thomas, M., Massimi, P., Jenkins, J. & Banks, L. (1995). HPV-18 E6 mediated inhibition of p53 DNA binding activity is independent of E6 induced degradation. Oncogene 10, 261-268.
35. Waga, S., Hannon, G. J., Beach, D. & Stillman, B. (1994). The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 369, 574-578.